RespireRx Pharmaceuticals Inc.
RSPI
$0.0021
$0.0011110.00%
OTC PK
| 09/30/2023 | 06/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -33.32% | 25.93% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -28.63% | 19.34% | |||
| Operating Income | 28.63% | -19.34% | |||
| Income Before Tax | 41.92% | -58.34% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 41.92% | -58.34% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 41.92% | -58.34% | |||
| EBIT | 28.63% | -19.34% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 63.41% | -32.26% | |||
| Normalized Basic EPS | 64.00% | -25.00% | |||
| EPS Diluted | 63.41% | -32.26% | |||
| Normalized Diluted EPS | 64.00% | -25.00% | |||
| Average Basic Shares Outstanding | 59.16% | 22.62% | |||
| Average Diluted Shares Outstanding | 59.16% | 22.62% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||